SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus on social platforms, driven by investor speculation over future supply burns and its evolving regulatory status as a digital commodity. While some community members remain deeply bullish, citing potential for long-term growth and institutional adoption, others are actively debating whether the asset is stagnant or primed for a significant breakout.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as active traders debate whether recent volatility and chart patterns signal a potential recovery or further downside, with a polarized community split between long-term holders anticipating a bull cycle and skeptics calling for lower support levels. Market discussions remain heavily focused on the interplay between technical momentum, staking rewards, and broader macroeconomic factors impacting alternative assets.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is currently the subject of intense buyout speculation, fueled by the recent FDA grant of a landmark formal evidentiary hearing for its jet lag treatment and the approval of its bipolar medication, Bysanti. While investors are actively debating the impact of management's confrontational FDA strategy and price suppression, the community is closely monitoring the stock for potential acquisition by major pharmaceutical players looking to secure its high-value pipeline.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a focal point for community speculation as traders monitor shifting institutional sentiment and the emergence of new ecosystem projects. Investors are actively debating potential price movements amidst broader market volatility, with many users focused on staking rewards and identifying early-stage tokens within the network's expanding meme coin landscape.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing heavy social media activity, with the community polarized between those aggressively accumulating during recent price volatility and skeptics dismissing it as a typical memecoin pump-and-dump cycle. Investors are closely monitoring key metrics like chain holder growth and upcoming token burn events, while sentiment remains highly volatile as the asset navigates broader market consolidation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors anticipate key regulatory milestones, specifically an upcoming FDA decision for ivonescimab. While some community members express frustration with recent price volatility and delays, others remain deeply bullish, pointing to strong trial data and a potential short squeeze as major catalysts for future growth.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as investors lean into the deep historical lore of the original 2011 meme, which has transitioned from a Bitcoin-mocking internet joke to an on-chain project on Solana. The community is buzzing over its potential to reach billion-dollar valuations, driven by active engagement, historical memes, and the backing of significant whale interest.

Maulcoin

Maulcoin is capturing attention as the community rallies around organic growth and a 'diamond hand' holding strategy to push toward a higher market cap. Enthusiastic investors are actively highlighting its trending status on social platforms and urging others to join the movement before further milestones are reached.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is seeing renewed market attention as traders monitor potential institutional interest and ETF speculation, fueling community debates over whether it can replicate its past breakout momentum. While some participants express frustration with price volatility and the broader memecoin landscape, others view the current consolidation as an accumulation phase in anticipation of a potential market-wide recovery tied to broader crypto sentiment.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is currently experiencing high volatility and significant social media attention as traders speculate on potential partnerships and a massive short squeeze. The community is sharply divided between those betting on a parabolic reversal fueled by low market cap dynamics and those warning of manipulative sell-offs following recent price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21.</li><li>Preclinical findings showed SLS009 triggered leukemia cell death by increasing caspase-3 activity and reducing survival proteins such as MCL-1 and survivin.</li><li>Investor focus remains centered on the Phase 3 Regal study evaluating GPS as a maintenance therapy for AML patients in remission after relapse.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) rose 1% in premarket trading on Thursday as investors positioned ahead of an upcoming cancer conference presentation and a closely watched survival milestone in the company’s Phase 3 acute myeloid leukemia (AML) trial.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 8% on Wednesday amid a volatile trading week.<h2 class="st-heading-2">AACR Preview: SLS009 Triggers Leukemia Cell Death Signals</h2>Sellas is preparing to present new preclinical data on its CDK9 inhibitor candidate SLS009 at the American Association for Cancer Research (AACR) annual meeting on April 21 in San Diego.Preclinical findings showed that SLS009 triggered leukemia cell death by increasing&nbsp;the&nbsp;activity of caspase-3, a key apoptosis protein, while lowering survival signals such as MCL-1 and survivin that help cancer cells persist. The drug also became more potent with repeated exposure, with early effects appearing within hours and strengthening over 24 hours.Notably, SLS009 remained active even in AML models carrying ASXL1 and TP53 mutations, which are associated with treatment resistance and poorer outcomes.<h2 class="st-heading-2">Investor Focus Remains On AML Survival Readout Timeline</h2>However, investor attention remains firmly focused on the company’s Phase 3 Regal trial evaluating GPS as a maintenance therapy for AML patients whose disease returned but later entered remission following additional treatment.GPS targets the Wilms Tumor-1 antigen, a protein commonly expressed across leukemia cells regardless of mutation status.The event-driven study will begin final analysis once 80 overall-survival events are recorded. Sellas previously said the contract research organization monitoring the trial had logged 72 events as of Dec. 26, bringing the study closer to the threshold required to initiate topline analysis.CEO Angelos Stergiou recently addressed speculation surrounding the timing of the readout on&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7444461539476197376/?originTrackingId=ExoqDp%2B3Mqnf9Ee3j3DVgA%3D%3D">LinkedIn</a>, noting that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than baseline expectations.Once the 80th event occurs, the company plans to proceed with database lock, statistical analysis, unblinding and disclosure of topline results.<h2 class="st-heading-2">How Does Retail Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has slipped to ‘bearish’ from ‘extremely bullish’ levels a month ago amid a 23% dip in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_d73af252d9.webp" alt="sls ss.png" width="965" height="143"><figcaption>SLS sentiment and message volume as of April 9 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Princeb/message/649792805">said</a> SLS is “truly shaping up to be a once in a lifetime moonshot win.&nbsp; Don't miss your chance.”<stembedurl>https://stocktwits.com/Princeb/message/649792805</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Torben96/message/649792114">said</a>, “GPS is a safe harbour now, the IDMC meeting will reveal this. We should be worth 2B Dollar already.”<stembedurl>https://stocktwits.com/Torben96/message/649792114</stembedurl>SLS stock has surged 367% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bbby-ceo-pulls-opendoor-into-everything-home-turnaround-bet/cZJgy2ORIrB">Bed Bath &amp; Beyond CEO Pulls Opendoor Into ‘Everything-Home’ Platform Pivot</a>

SLS stock has surged 367% over the past year. (Photo credit: Getty Images)

SLS Stock Rises Premarket Ahead Of Cancer Summit This Month – Investors Eye Phase 3 AML Trial Milestone

SLS Stock - CEO Angelos Stergiou recently said that the slower accumulation of survival events can sometimes reflect longer patient survival.

Equity

CEO Angelos Stergiou recently said that the slower accumulation of survival events can sometimes reflect longer patient survival.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 9.5%  - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.5% Higher - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 7.7%  - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 7.7% - What's Next...

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

<ul class="summary-bullets"><li>Investors weighed conflicting signals from Middle East diplomacy and braced for fresh labor market data.</li><li>AI trade tensions and regulatory risks kept Nvidia and chip-linked names under pressure.</li><li>U.S. President Trump will be holding a cabinet meeting at 10:00 am ET today.&nbsp;</li></ul>U.S. stock futures fell early Thursday as investors continued to parse the geopolitical developments in the Middle East. Amid conflicting reports, Iran is said to be reviewing a U.S. peace proposal delivered through Pakistan. Traders are also bracing for fresh macro signals with jobless claims data due later today. U.S. President Trump will be holding a cabinet meeting at 10:00 am ET today.&nbsp;As of 4:00 a.m. ET on Thursday, Dow, S&amp;P 500, and Nasdaq futures fell 0.4%, and Russell 2000 futures were down 0.6%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has been languishing at ‘extremely bearish’ amid high trading volume.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chipmaker remains in focus, with retail sentiment weakening to ‘bearish’ on Stocktwits. Calls are growing louder in Washington, with U.S. Senators Warren and Banks pushing to freeze export licenses over national security concerns.Meta Inc (META):&nbsp;It has lost another lawsuit alleging they made misleading claims about platform safety, adding to its growing list of legal headwinds.Destiny Tech100 (DXYZ):&nbsp;Garnering heavy retail interest as speculation around a potential SpaceX IPO grows this week.Micron (MU), Sandisk (SNDK):&nbsp;Memory stocks took a hit after reports that Google’s new AI model architecture could bring a significant impact on memory requirements.Super Micro (SMCI): The stock remained under pressure as shareholders filed a securities fraud lawsuit following recent allegations of chip smuggling.ImmunityBio (IBRX): The retail favorite biotech stock is back on traders’ radar after the company highlighted progress in its bladder cancer program and expanded trials targeting severe pneumonia and ARDS.&nbsp;Sellas Life Sciences (SLS): This pharma stock is gaining ground amid&nbsp;retail-trader speculation that Pfizer (PFE) may target the firm for an acquisition.urban-Gro (UGRO): The stock fell over 10% in early pre-market trading after surging over 400% in the previous session. Retail is bullish on the company’s new exposure to India’s fast-growing cricket economy following its merger with Flash Sports &amp; Media.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Adma Biologics (ADMA), Upstart Holdings (UPST), Moonlake Immunotherapeutics (MLTX), NextDecade Corporation (NEXT), and Alphabet Inc (GOOGL).&nbsp;Other Catalysts To WatchOn the economic front, traders will be watching for the release of continuing jobless claims data at 8:30 am ET. Also keep an eye on commentary from a whole host of Fed Governors’ speeches through the day, including Fed Vice Chair for Supervision Michael Barr.On earnings radar, watch out for quarterly reports from Pulmatrix (PULM), BioRestorative Therapies Inc (BRTX), and POET Technologies Inc (POET), among others, today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall Ahead Of Jobless Claims Data: Why NVDA, META, DXYZ, IBRX, SLS Are Keeping Traders Engaged Today

Data from Stocktwits shows that traders remain ‘extremely bearish’ on SPY and QQQ. 

<ul class="summary-bullets"><li>Investors compared Merck’s willingness to pay a 42% premium for mid-stage leukemia drug TERN-701 with Sellas’ AML pipeline opportunity.</li><li>Several retail investors pointed to Pfizer as a potential buyer, citing its ongoing expansion in hematologic cancers and need for post-COVID growth drivers.</li><li>Attention is focused on the Phase 3 Regal trial of GPS in AML relapse patients, which had recorded 72 of 80 required death events for final analysis as of late December.</li></ul>Shares of Sellas Life Sciences (SLS)&nbsp;jumped over 6% on Wednesday as Merck’s $6.7 billion acquisition of Terns Pharmaceuticals triggered renewed buzz on potential takeover targets across blood-cancer drug pipelines.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has risen 41% this quarter and has surged over 300% over the past year.<h2 class="st-heading-2">Merck’s Terns Deal Spurs Leukemia Interest</h2>Merck said it would acquire Terns for $53 per share in cash, representing a 42% premium to the 90-day average before the deal’s announcement.The acquisition adds TERN-701, an oral leukemia drug currently in early-to-mid-stage clinical testing, to Merck’s blood-cancer pipeline. The treatment is being studied for patients with chronic myeloid leukemia whose disease did not respond well to earlier therapies or who could not tolerate them.Now, retail investors are drawing comparisons between Merck’s willingness to pay billions for a mid-stage leukemia asset and the perceived commercial opportunity around Sellas’ pipeline.<h2 class="st-heading-2">Retail Traders Bet On Pfizer As Potential Buyer</h2>On Stocktwits, retail sentiment for SLS has remained in the ‘bearish’ zone over the past week amid an over 350% surge in message volume this quarter. The stock’s watcher base has jumped 20% over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_7ab67c1205.webp" alt="sls ss.png" width="968" height="144"><figcaption>SLS sentiment and message volume as of March 26 | Source: Stocktwits</figcaption></figure>Sentiment over the past day has increasingly centered on Pfizer as a potential acquirer following the Merck-Terns deal. One trader&nbsp;<a href="https://stocktwits.com/MarcoFla99/message/648580457">said</a>, “My $$ is on PFE to acquire SLS.”The investor pointed to Pfizer’s ongoing clinical work on Mylotarg in CD33-positive acute myeloid leukemia (AML), noting that the company is conducting a prospective surveillance study to evaluate the drug’s safety and effectiveness in newly diagnosed patients as part of its push into hematologic cancers.Another trader argued Pfizer may be seeking a major oncology win following the pandemic-era revenue decline,&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/648587881">saying</a>, “They need a clear win to bury the COVID era and leave it behind… What is better than a cancer moonshot?”Another investor&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/648587881">highlighted</a> motivations behind possible acquisitions, saying “PFE stock and shareholders [are] looking desperately for a powerful boost.”<h2 class="st-heading-2">Retail Traders Run Buyout Valuation Scenarios</h2>One retail investor&nbsp;<a href="https://stocktwits.com/Duncan74/message/648577739">estimated</a> that applying a typical 5x-8x peak-sales multiple to projected revenue of about $5.5 billion for Sellas’ lead AML candidate, Galinpepimut-S (GPS), and $1.2 billion for its CDK9 inhibitor, SLS-009, could imply a valuation range of roughly $33.5 billion to $53.6 billion.Another trader compared the Merck-Terns transaction directly with Sellas’ opportunity: “If TERN was acquired by MRK for 8.8b. and our product has market size smaller than TERN. our upside should be 4x-6x?”A separate user discussed potential acquisition structure scenarios,&nbsp;<a href="https://stocktwits.com/JdlawVT40/message/648584776">saying</a>, “Wouldn’t a PFE stock purchase be sweet. All long term holding period and a 6.30 dividend. Four to one share SLS.”Another trader&nbsp;<a href="https://stocktwits.com/Johnmtnb2018/message/648533707">suggested</a> the setup for a deal may already be in place: “The table is now fully set for interested pharma’s to finish a deal!” One investor also&nbsp;<a href="https://stocktwits.com/Laacy/message/648584092">outlined</a> a portfolio strategy for a possible acquisition, saying, “If PFE offers id sell my options. Keep 33% as pfizer shares if share based and sell the rest.”<h2 class="st-heading-2">GPS Catalyst Aligns With Pfizer Moves</h2>Investor attention remains focused on Sellas’ Phase 3 Regal trial evaluating GPS in AML patients whose cancer returned and then went back into remission after additional treatment. The study is designed to reach its final analysis after 80 patient death events, with 72 recorded as of Dec. 26 while the trial remained fully blinded, placing the program closer to a potential results-driven catalyst.Merck’s move to buy TERN-701 underscores continued demand for blood-cancer assets, while Pfizer has been stepping up investment in oncology as it looks to rebuild growth after the sharp decline in COVID vaccine revenues and increasing competition across several aging products.&nbsp;The company has expanded its cancer pipeline through initiatives including its $1.25 billion upfront licensing deal with 3SBio, ongoing development of Mylotarg in AML and progress with Tukysa in breast cancer.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-vs-tern-which-stock-has-more-upside-ahead-of-keytruda-patent-cliff/cZ3YKepRI16">SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff</a>

SLS stock has risen 41% this quarter and has surged over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps After Merck's Tern Deal Sparks Buyout Buzz In Blood-Cancer Space: Retail Bets On This Big Pharma Suitor

Merck’s acquisition of Terns underscores strong big-pharma demand for blood-cancer assets, as Pfizer also expands its oncology pipeline.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff

SLS vs TERN Stock - Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.5%  - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.5% - Time to Sell...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 12.9% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 12.9% - Here's What Happened...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Investors are closely monitoring the potential for a mid-trial clinical halt by the IDMC based on groundbreaking efficacy data.

A massive accumulation of over 53 million shorted shares is creating high expectations for a violent repricing event.

The upcoming oncology conference is expected to be a major catalyst for company awareness and potential strategic updates.

Discussions are heating up around the potential curative capabilities of proprietary peptide technologies for various cancer indications.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc